What's in ModernaTX, Inc.'s pipeline?

ModernaTX, Inc. has 96 drugs in our index: 6 marketed, 0 filed, 13 in Phase 3, 27 in Phase 2, 50 in Phase 1.

Which companies overlap with ModernaTX, Inc.'s portfolio?

Top competitors by shared drug class: National Institute of Allergy and Infectious Diseases (NIAID), Sanofi Pasteur, a Sanofi Company, MedImmune LLC, Assistance Publique - Hôpitaux de Paris, Novartis.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/modernatx-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-06-09 · How we verify

ModernaTX, Inc. — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ModernaTX, Inc. pipeline: 6 marketed, 0 filed, 13 Phase 3, 27 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

6 marketed 0 filed 13 Phase 3 27 Phase 2 50 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
mRNA-1283	mRNA-1283	marketed	mRNA vaccine	HPV16 and HPV18 antigens (E6 and E7 proteins)	Oncology
Fluzone HD	Fluzone HD	marketed
Influenza Vaccine 2	Influenza Vaccine 2	marketed
mRNA-1273.712	mRNA-1273.712	marketed
Fluarix Quadrivalent	Fluarix Quadrivalent	marketed
mRNA-1273 Variant-containing Formulation	mRNA-1273 Variant-containing Formulation	marketed	mRNA vaccine	SARS-CoV-2 spike protein (variant-specific)	Immunology / Infectious Disease
mRNA-1010	mRNA-1010	phase 3	Personalized neoantigen vaccine	Patient-specific tumor neoantigens	Oncology
Alpharix® Tetra	Alpharix® Tetra	phase 3	mRNA vaccine		Immunology / Infectious Disease or Oncology
Afluria® Quadrivalent	Afluria® Quadrivalent	phase 3	Inactivated influenza vaccine		Immunology / Infectious Disease
Influsplit® Tetra	Influsplit® Tetra	phase 3	mRNA vaccine	Influenza hemagglutinin and neuraminidase antigens	Immunology / Infectious Disease
mRNA-1403	mRNA-1403	phase 3	mRNA vaccine	SARS-CoV-2 spike protein	Infectious Disease
Licensed Spikevax Vaccine	Licensed Spikevax Vaccine	phase 3	mRNA vaccine	SARS-CoV-2 spike protein (S protein)	Immunology / Infectious Disease

Therapeutic area mix

Immunology / Infectious Disease · 5
Infectious Disease · 3
Oncology · 2
Infectious disease · 1
Musculoskeletal · 1
Infectious Diseases · 1
Immunology / Infectious Disease or Oncology · 1
Immunology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

National Institute of Allergy and Infectious Diseases (NIAID) · 2 shared drug classes
Sanofi Pasteur, a Sanofi Company · 2 shared drug classes
MedImmune LLC · 2 shared drug classes
Assistance Publique - Hôpitaux de Paris · 2 shared drug classes
Novartis · 2 shared drug classes
Protein Sciences Corporation · 2 shared drug classes
GlaxoSmithKline · 2 shared drug classes
Seqirus · 2 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for ModernaTX, Inc.:

Cite this brief

Drug Landscape (2026). ModernaTX, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/modernatx-inc. Accessed 2026-06-09.